Humacyte HUMA
NASDAQ HUMA
$0.52 -0.02 (-3.12%)
As of: Sep 30, 2026 · 2:49 PM EDT

Humacyte (HUMA) Net Margin (2020 - 2026)

Updated

Humacyte (HUMA) reported Net Margin of -9064.53% for Q2 2026, up 3446.43 percentage points from -12510.96% a year earlier but down 5505.14 percentage points from the prior quarter.

Analysis

Humacyte (HUMA) Net Margin (2020 - 2026) Analysis & Trends

Over the twelve months ended Jun 30, 2026, Humacyte's Net Margin came in at -4560.82%, up 2610.45 percentage points year-over-year; for FY2025, it was -2003.58%.

  • Five-year quarterly Net Margin spans a low of -13096.68% in Q3 2021 and a high of 7570.41% in Q1 2025.
  • Per Business Quant data, the three quarters before Q2 2026 came in at -3559.39% (Q1 2026), -5311.35% (Q4 2025) and -2325.37% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Margin (Qtr)
1 Johnson & Johnson 645.01 Bn 563.54 Bn 17.26 Bn 21.86%
2 AbbVie 465.23 Bn 438.39 Bn 12.70 Bn 21.27%
3 Merck 368.40 Bn 322.83 Bn 12.21 Bn -8.04%
4 Novartis Ag 278.02 Bn 233.89 Bn 11.24 Bn 22.61%
5 Astrazeneca 254.57 Bn 228.13 Bn 12.86 Bn 18.81%
6 Amgen 229.02 Bn 184.42 Bn 7.24 Bn 23.62%
7 Gilead Sciences 187.74 Bn 161.85 Bn 6.22 Bn -134.51%
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn -1.65%
9 Vertex Pharmaceuticals 133.45 Bn 105.45 Bn 2.84 Bn 32.99%
10 Humacyte 147.23 Mn 147.23 Mn -825,000.00 -9,064.53%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -9,064.53%
Mar 31, 2026 -3,559.39%
Dec 31, 2025 -5,311.35%
Sep 30, 2025 -2,325.37%
Jun 30, 2025 -12,510.96%
Mar 31, 2025 7,570.41%
Sep 30, 2021 -13,096.68%
Sep 30, 2020 -4.48%
API Access

Humacyte Net Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=net-margin&ticker=HUMA&period=max&api_key=YOUR_API_KEY